Facebook Twitter LinkedIn Google Plus RSS

CorMedix to raise $3M in concurrent offerings

By ,

Bridgewater-based pharmaceutical company CorMedix announced today it has entered into two securities purchase agreements with existing institutional investors.

According to the announcement, the company entered into a securities purchase agreement with an existing institutional investor, pursuant to which it has agreed to sell 150,000 shares of series C-1 nonvoting convertible preferred stock and a warrant to purchase up to 750,000 shares of common stock.

CorMedix also entered a separate securities purchase agreement with another existing institutional investor, pursuant to which it has agreed to sell 150,000 shares of series C-2 nonvoting convertible preferred stock and a warrant to purchase up to 750,000 shares of common stock, for aggregate gross proceeds of $3 million.

More From This Industry

Write to the Editorial Department at editorial@njbiz.com

Related Stories

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close